Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

And Eli Lilly's cloud also has a pair of silver linings that investors ... tirzepatide -- a therapy for type 2 diabetes and ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

We recently compiled a list of the 10 Best Reddit Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly And Co.

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

Healthcare giant Eli Lilly (NYSE: LLY) has been trading at an inflated valuation for some time thanks to excitement around ...